Horner syndrome

Summary

Horner syndrome (MONDO:0001294) is a disease and 6 clinical trials. Top therapeutic interventions include ropivacaine. A subtype of autonomic neuropathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Horner syndrome
Mondo ID	MONDO:0001294
MeSH	D006732
DOID	DOID:11486
ICD-10-CM	G90.2
ICD-11	178756462
NCIT	C28155
SNOMED CT	192915005
UMLS	C0019937
MedGen	5616
Is cancer (heuristic)	no

Also known as: Bernard-Horner syndrome · Horner syndrome · Horner’s syndrome · oculosympathetic palsy

Disease family

This is a subtype of autonomic neuropathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autonomic nervous system disorder › autonomic neuropathy › Horner syndrome

Related subtypes (1): diabetic autonomic neuropathy

Subtypes (1): congenital Horner syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03615508	PHASE4	TERMINATED	Exploration of Pupil Dilation in Horner’s Patients Taking Flomax
NCT01958801	Not specified	COMPLETED	Clinical Efficacy of Supraclavicular Block for Arthroscopic Shoulder Surgery
NCT02130739	Not specified	COMPLETED	Horner’s SD After Thoracic Epidural Block
NCT02978079	Not specified	UNKNOWN	Pupillometry in Horner’s Syndrome
NCT03514342	Not specified	COMPLETED	The Effects of Horner’s Syndrome Developing After Interscalene Brachial Plexus Block on Autonomic Nervous Activity
NCT04642612	Not specified	TERMINATED	Cerebral Blood Flow Evaluation With Trancranial Doppler After Interscalene Nerve Block

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ROPIVACAINE	4	2